Acute Respiratory Distress Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030

Posted on
by

DelveInsight’s “Acute Respiratory Distress Syndrome (ARDS) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS) , historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients.

Acute Respiratory Distress Syndrome Epidemiology Segmentation in 7MM from 2017 to 2030

  • Total Incident Population of ARDS
  • Severity-specific Incidence of ARDS
  • Incidence of ARDS by Risk Factors

 

Acute Respiratory Distress Syndrome Epidemiology

  • The total incident population of ARDS in 7MM in 2017 was 7,99,872
  • The incidence of ARDS in the United States in 2017 was 4, 95,655 

 

Acute Respiratory Distress Syndrome Market

Acute Respiratory Distress Syndrome market in the 7MM is rising at a CAGR of 9.55% during the study period (2017–2030).

 

Acute Respiratory Distress Syndrome Emerging Drugs

  1. Traumakine: Faron Pharmaceuticals
  2. Bio-11006: BioMarck Pharmaceuticals
  3. MultiStem: Athersys
  4. Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH
  5. Ultomiris (ravulizumab-cwvz): Alexion Pharma
  6. Soliris (eculizumab): Alexion Pharma

 

Request for sample pages

Table of contents

1. Key Insights

2. Executive Summary of Acute Respiratory Distress Syndrome (ARDS)

3. Competitive Intelligence Analysis for Acute Respiratory Distress Syndrome (ARDS)

4. Acute Respiratory Distress Syndrome (ARDS) : Market Overview at a Glance

4.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Share (%) Distribution in 2017

4.2. Acute Respiratory Distress Syndrome (ARDS) Total Market Share (%) Distribution in 2030

5. Acute Respiratory Distress Syndrome (ARDS) : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Acute Respiratory Distress Syndrome (ARDS) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Acute Respiratory Distress Syndrome (ARDS) Treatment and Management

8.2. Acute Respiratory Distress Syndrome (ARDS) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Acute Respiratory Distress Syndrome (ARDS) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Acute Respiratory Distress Syndrome (ARDS) : Seven Major Market Analysis

13.1. Key Findings

13.2. Acute Respiratory Distress Syndrome (ARDS) Market Size in 7MM

13.3. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in the United States

15.1.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in Germany

15.3.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in France

15.4.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in Italy

15.5.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in Spain

15.6.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in the United Kingdom

15.7.2. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Acute Respiratory Distress Syndrome (ARDS) Total Market Size in Japan

15.8.3. Acute Respiratory Distress Syndrome (ARDS) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Acute Respiratory Distress Syndrome (ARDS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/